Take that, Omicron. Results of a trial looking at a combination COVID-19 vaccine booster reveals a “robust antibody response” against the Omicron variant, vaccine manufacturer Moderna announced Wednesday.
A US study found that Omicron may be intrinsically as severe as previous coronavirus variants, contradicting assumptions that the strain was more transmissible, but less severe. The study, which was published as a pre-print on Research Square on May 2, controlled four factors such as demographics, vaccination status, and the Charlson comorbidity index, which predicts the risk